|
JP2020162622A
|
|
Ultra-potent neutralization of cytokines by multispecific antibodies and uses thereof
|
|
GB201522541D0
|
|
Compositions
|
|
WO2015165480A1
|
|
Human cytomegalovirus vaccine compositions and method of producing the same
|
|
JP2014087349A
|
|
Human cytomegalovirus neutralizing antibodies and use thereof
|
|
TN2011000028A1
|
|
Neutralizing anti-influenza a virus antibodies and uses therof
|
|
WO2011092593A2
|
|
Hiv-1 neutralizing antibodies and uses thereof
|
|
TN2010000621A1
|
|
Human cytomegalovirus neutralizing antibodies and use thereof
|
|
MX2011003588A
|
|
Dengue virus neutralizing antibodies and uses thereof.
|
|
WO2010010466A2
|
|
Neutralizing anti-influenza a virus antibodies and uses thereof
|
|
US2011159001A1
|
|
CROSS-NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES TO SARS-CoV AND METHODS OF USE THEREOF
|
|
GB0819376D0
|
|
Method for culturing human plasma cells
|
|
EP2960250A1
|
|
Human cytomegalovirus neutralising antibodies and use thereof
|
|
EP1597280A2
|
|
Monoclonal antibody production by ebv transformation of b cells
|
